Bridge-to-Decision Therapy With a Continuous-Flow External Ventricular Assist Device in Refractory Cardiogenic Shock of Various Causes
- 1 September 2014
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 7 (5) , 799-806
Abstract
Background—: Mortality for refractory cardiogenic shock remains high. In this patient cohort, there have been mixed results in mechanical circulatory support device use as a bridge-to-decision therapy. We evaluated a continuous-flow external ventricular assist device (VAD), CentriMag VAD (Thoratec Corp., Pleasanton, CA), in patients with various causes of refractory cardiogenic shock. Methods and Results—: This is a retrospective review of adult patients who underwent surgical CentriMag VAD insertion as bridge-to-decision therapy. From January 2007 through June 2012, 143 patients received CentriMag VAD. The cause of refractory cardiogenic shock was failure of medical management in 71 patients, postcardiotomy shock in 37, graft failure post–heart transplantation in 22, and right ventricular failure post–implantable left VAD in 13. Mean age was 52±16 years, and 71% were in INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support) profile 1. Among 158 device runs, device configuration was BiVAD in 67%, isolated right VAD in 26%, and isolated left VAD in 8%. Median duration of support was 14 days (interquartile range, 8–26). Survival was 69% at 30 days and 49% at 1 year. The next destination after the CentriMag VAD was myocardial recovery in 30%, device exchange to an implantable VAD in 15%, and heart transplantation in 18%. The failure of medical management and the graft failure post–heart transplantation groups had higher 30-day survival compared with the postcardiotomy shock group. Major bleeding events occurred in 33% and cerebrovascular accidents in 14%. There was no CentriMag pump failure or thrombosis. Conclusions—: Bridge-to-decision therapy with CentriMag VAD is feasible in a variety of refractory cardiogenic shock settings. Patients with postcardiotomy shock have inferior survival.Keywords
This publication has 28 references indexed in Scilit:
- Outcomes of a multicenter trial of the Levitronix CentriMag ventricular assist system for short-term circulatory supportThe Journal of Thoracic and Cardiovascular Surgery, 2011
- Clinical Experience Using the Levitronix CentriMag System for Temporary Right Ventricular Mechanical Circulatory SupportThe Journal of Heart and Lung Transplantation, 2009
- Early planned institution of biventricular mechanical circulatory support results in improved outcomes compared with delayed conversion of a left ventricular assist device to a biventricular assist deviceThe Journal of Thoracic and Cardiovascular Surgery, 2009
- Thirty-Year Trends (1975 to 2005) in the Magnitude of, Management of, and Hospital Death Rates Associated With Cardiogenic Shock in Patients With Acute Myocardial InfarctionCirculation, 2009
- Pediatric Application of the Thoratec CentriMag BiVAD as a Bridge to Heart TransplantationThe Journal of Thoracic and Cardiovascular Surgery, 2008
- Connecting the Centrimag Levitronix Pump to Berlin Heart Excor Cannulae; A New Approach to Bridge to BridgeThe Journal of Heart and Lung Transplantation, 2008
- Venoarterial Extracorporeal Membrane Oxygenation (VA-ECMO) in Pediatric Cardiac SupportThe Annals of Thoracic Surgery, 2006
- Right Heart Failure After Left Ventricular Assist Device Implantation in Patients With Chronic Congestive Heart FailureThe Journal of Heart and Lung Transplantation, 2006
- Performance and Reliability of the CPB/ECMO Initiative Forward Lines Casualty Management SystemASAIO Journal, 2005
- Early Revascularization in Acute Myocardial Infarction Complicated by Cardiogenic ShockNew England Journal of Medicine, 1999